Effect of the cytochrome P450 2D6*10 allele on risperidone metabolism in Japanese psychiatric patients

Human Psychopharmacology

Volumn 27, Issue 1, 2012, Pages 43-46

  Suzuki, Yutaro ^a   Fukui, Naoki ^a   Tsuneyama, Nobuto ^a   Watanabe, Junzo ^a   Ono, Shin ^a   Sugai, Takuro ^a   Saito, Mami ^a   Inoue, Yoshimasa ^b   Someya, Toshiyuki ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b Mitsubishi Tanabe Pharma Factory Ltd   (Japan)

Author keywords

9 OH RIS; active moiety; pharmacogenetics; pharmacokinetics

Indexed keywords

CYTOCHROME P450 2D6; PALIPERIDONE; RISPERIDONE;

ADULT; ALLELE; ARTICLE; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GENOTYPE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS; ISOXAZOLES; JAPAN; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; PYRIMIDINES; RISPERIDONE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84856317915     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1260     Document Type: Article

References (19)

1. van Beijsterveldt LE, Geerts RJ, Leysen JE, et al,. 1994. Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology (Berl) 114: 53-62. (Pubitemid 24150520)
2. Cho HY, Lee, YB,. 2006. Pharmacokinetics and bioequivalence evaluation of risperidone in healthy male subjects with different CYP2D6 genotypes. Arch Pharm Res 29: 525-533.
3. Fitzgerald P, Dinan TG,. 2008. Prolactin and dopamine: what is the connection? A review article. J Psychopharmacol 22 (2 Suppl): 12-19.
4. Gan SH, Ismail R, Wan Adnan WA, et al,. 2002. Correlation of tramadol pharmacokinetics and CYP2D6*10 genotype in Malaysian subjects. J Pharm Biomed Anal 30: 189-195. (Pubitemid 35013483)
5. Hendset M, Molden E, Refsum H, et al,. 2009. Hermann M. Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone. J Clin Psychopharmacol 29: 537-541.
6. Huang ML, Van Peer A, Woestenborghs R, et al,. 1993. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 54: 257-268. (Pubitemid 23294526)
7. Johansson I, Oscarson M, Yue QY, et al,. 1994. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 46: 452-459. (Pubitemid 24296678)
8. Jovanović N, Božina N, Lovrić M, et al,. 2010. The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone. Eur J Clin Pharmacol 66: 1109-1117.
9. Leon J, Susce MT, Pan RM, et al,. 2007. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 40: 93-102. (Pubitemid 46910379)
10. Lostia AM, Mazzarini L, Pacchiarotti I, et al,. 2009. Serum levels of risperidone and its metabolite, 9-hydroxyrisperidone: correlation between drug concentration and clinical response. Ther Drug Monit 31: 475-481.
11. Mihara K, Kondo T, Yasui-Furukori N, et al,. 2003. Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia. Ther Drug Monit 25: 287-293. (Pubitemid 36638171)
12. Nakagami T, Yasui-Furukori N, Saito M, et al,. 2005. Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition. Clin Pharmacol Ther 78: 43-51. (Pubitemid 40956930)
13. Novalbos J, Lõpez-Rodríguez R, Román M, et al,. 2010. Effects of CYP2D6 genotype on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. J Clin Psychopharmacol 30: 504-511.
14. Roh HK, Chung JY, Oh DY, et al,. 2001. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br J Clin Pharmacol 52: 265-271.
15. Steen VM, Andreassen OA, Daly AK, et al,. 1995. Detection of the poor metabolizer-associated CYP2D6 (D) gene deletion allele by long-PCR technology. Pharmacogenetics 5: 215-223.
16. Suzuki Y, Fukui N, Watanabe J, et al,. 2010. Gender differences in the relationship between the risperidone metabolism and the plasma prolactin levels in psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry 34: 1266-1268.
17. Xiang Q, Zhao X, Zhou Y, et al,. 2010. Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. J Clin Pharmacol 50: 659-666.
18. Yagihashi T, Mizuno M, Chino B, et al,. 2009. Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia. Hum Psychopharmacol 24: 301-308.
19. Yoo HD, Lee SN, Kang HA, et al,. 2011. Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10. Br J Pharmacol 164: 433-443.